These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32820965)

  • 1. Development of chemotherapeutics for unresectable advanced esophageal cancer.
    Imazeki H; Kato K
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1083-1092. PubMed ID: 32820965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
    Leng XF; Daiko H; Han YT; Mao YS
    Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.
    Hirano H; Kato K
    Jpn J Clin Oncol; 2019 May; 49(5):412-420. PubMed ID: 30920626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    Wang WT; Guo CQ; Cui GH; Zhao S
    World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.
    Zhang Y; Li Z; Huang Y; Xu Y; Zou B
    Expert Rev Clin Immunol; 2024 Aug; 20(8):971-984. PubMed ID: 38884604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
    Yan T; Cui H; Zhou Y; Yang B; Kong P; Zhang Y; Liu Y; Wang B; Cheng Y; Li J; Guo S; Xu E; Liu H; Cheng C; Zhang L; Chen L; Zhuang X; Qian Y; Yang J; Ma Y; Li H; Wang F; Liu J; Liu X; Su D; Wang Y; Sun R; Guo S; Li Y; Cheng X; Liu Z; Zhan Q; Cui Y
    Nat Commun; 2019 Apr; 10(1):1670. PubMed ID: 30975989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Nikai H; Baba S; Chiba T; Kimura T; Takahara T; Otsuka K; Nitta H; Mizuno M; Kimura Y; Koeda K; Sasaki A
    Asian J Endosc Surg; 2020 Apr; 13(2):152-159. PubMed ID: 31313511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy as a cytoprotective mechanism in esophageal squamous cell carcinoma.
    Hall TM; Tétreault MP; Hamilton KE; Whelan KA
    Curr Opin Pharmacol; 2018 Aug; 41():12-19. PubMed ID: 29677645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.
    Pape M; Vissers PAJ; de Vos-Geelen J; Hulshof MCCM; Gisbertz SS; Jeene PM; van Laarhoven HWM; Verhoeven RHA
    Cancer Sci; 2022 Mar; 113(3):1038-1046. PubMed ID: 34986523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Iwabu J; Yamashita S; Takeshima H; Kishino T; Takahashi T; Oda I; Koyanagi K; Igaki H; Tachimori Y; Daiko H; Nakazato H; Nishiyama K; Lee YC; Hanazaki K; Ushijima T
    Sci Rep; 2019 Sep; 9(1):13347. PubMed ID: 31527639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review).
    Zhang W; Zhu M; Xiang Y; Sun Y; Li S; Cai J; Zeng H
    Oncol Rep; 2024 May; 51(5):. PubMed ID: 38456536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
    Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of p-p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance.
    Wang Z; Zhang J; Li M; Kong L; Yu J
    Thorac Cancer; 2020 Jan; 11(1):130-139. PubMed ID: 31755241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway.
    Zhang Y; Chen W; Wang H; Pan T; Zhang Y; Li C
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1209-1218. PubMed ID: 31529206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and translational advances in esophageal squamous cell carcinoma.
    Reichenbach ZW; Murray MG; Saxena R; Farkas D; Karassik EG; Klochkova A; Patel K; Tice C; Hall TM; Gang J; Parkman HP; Ward SJ; Tétreault MP; Whelan KA
    Adv Cancer Res; 2019; 144():95-135. PubMed ID: 31349905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
    Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
    Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.